Gilead Sciences says it will charge U.S. hospitals $3,120 for a typical patient with commercial insurance for the COVID-19 drug remdesivir, which "interferes with the new coronavirus’s
ability to replicate within a patient’s cells,” according to The Wall Street Journal.
“Under the company’s plans, Gilead will charge a higher price
for patients with private insurance in the U.S., and a lower price for U.S. government health programs like Medicare and all other developed countries that insure their patients directly."
Read the whole story at The Wall Street Journal »